Document is current
Any future updates will be listed below
-
Authors
Serrano, César https://orcid.org/0000-0003-1416-8739
Vivancos, Ana
López-Pousa, Antonio
Matito, Judit
Mancuso, Francesco M.
Valverde, Claudia
Quiroga, Sergi
Landolfi, Stefania
Castro, Sandra
Dopazo, Cristina
Sebio, Ana
Virgili, Anna C.
Menso, María M.
Martín-Broto, Javier
Sansó, Miriam
García-Valverde, Alfonso
Rosell, Jordi
Fletcher, Jonathan A.
George, Suzanne
Carles, Joan
Arribas, Joaquín
-
Funding
Funding for this research was provided by:
FERO Foundation (2015)
Fundación Científica Asociación Española Contra el Cáncer (JP Barcelona)
Instituto de Salud Carlos III (PI16/01371)
- License Information
-
More Information
Article History
Received: 16 July 2019
Accepted: 31 January 2020
First Online: 5 February 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board from Vall d’Hebron University Hospital (#PR (AG)216/2015) and Sant Pau University Hospital (#25/2015). Written informed consent was obtained from all patients to donate blood samples and tumor tissue.
: Not applicable.
: C.S. has received research grants from Deciphera Pharmaceuticals, Bayer Healthcare and Pfizer, Inc.; consulting fees (advisory role) from Deciphera Pharmaceuticals and Blueprint Medicines; payment for lectures from Bayer Healthcare; and travel grants from Pharmamar, Pfizer, Bayer Healthcare, Novartis and Lilly. S.G. has not conflict of interest directly related to this manuscript, although the content is related to Blueprint Medicines, Deciphera Pharmaceuticals and AstraZeneca consulting fees/honorarium.
